argenx SE
ARGX · EURONEXT · EUR
€728.40
+22.80 3.23%todayNot financial advice.
- Open
- 733.80
- Day range
- 719.20 - 745.60
- 52-week range
- 568.40 - 925.00
- Volume
- 160.85K
- Market cap
- 49.75B
- P/E ratio
- 32.35
- EPS
- 27.18
- Dividend yield
- 0.00%
- Beta
- 1.49
Performance
W
−12.77%
1M
−15.99%
3M
−8.84%
6M
+7.12%
YTD
+2.10%
Y
+6.24%
5Y
+178.44%
All
+8,469.41%
In the news
Oct 8
Argenx Sjogrens Trial Failure Drags Down Immunovant and Roivant Shares
Argenx stopped its late-stage Sjogren’s disease trial, raising doubts about a similar drug class being developed by rival Immunovant.
Company news
Oct 8
argenx SE Halts Phase 3 UNITY Trial of Efgartigimod in Sjogren's Disease
argenx SE is halting its Phase 3 UNITY trial of efgartigimod in Sjogren's disease after an interim analysis showed the drug was unlikely to succeed.
Company news
Oct 8
argenx SE Reports Positive Phase 2 Trials for Celiac Disease Drug FB102
argenx SE has announced positive Phase 2 clinical trial results for its celiac disease treatment FB102, clearing the way for Phase 3 studies.
Company news
Embed on your site
Embed docsAdd a live price card or a chart to any page. Free, no sign-up; cards refresh every minute and link back here.
<iframe src="https://stocks.freetheai.org/embed/EURONEXT-ARGX" width="340" height="170" style="border:0;max-width:100%" loading="lazy" title="argenx SE (ARGX) - FreeTheAI Stocks"></iframe>
<p style="font-size:12px"><a href="https://stocks.freetheai.org/symbols/EURONEXT-ARGX">ARGX stock price</a> by FreeTheAI Stocks</p>